Why the study?
The prognostic utility of high-sensitivity cardiac troponin T (hs-cTnT) on clinical outcomes in cardiac sarcoidosis remains unknown.
Does elevated high-sensitivity cardiac troponin T predict adverse clinical outcomes in patients with chronic phase cardiac sarcoidosis?
Does elevated high-sensitivity cardiac troponin T predict adverse clinical outcomes in patients with chronic phase cardiac sarcoidosis?
Elevated high-sensitivity cardiac troponin T is an effective prognostic biomarker for predicting cardiac death and adverse events in patients with chronic phase cardiac sarcoidosis.
Answers are grounded in this paper and cite their sources.
May aid risk stratification in chronic cardiac sarcoidosis; hypothesis-generating and requires prospective validation.
BACKGROUND: The prognostic utility of high-sensitivity cardiac troponin T (hs-cTnT) on clinical outcomes in cardiac sarcoidosis (CS) remains unknown, so we evaluated hs-cTnT in the chronic phase of CS. METHODS AND RESULTS: We enrolled 92 consecutive patients with CS in the chronic phase after medical therapies. Patients were divided into 2 groups according to hs-cTnT level: 0.014 ng/mL: high hs-cTnT (n=37); normal hs-cTnT (n=55). The primary endpoint was cardiac death and the secondary endpoint was cardiac death, ventricular tachyarrhythmias, or hospitalization for heart failure. The mean age of patients was 63±11 years, and 75 received steroid treatment. During a median follow-up of 63 months, there were 9 cardiac deaths: 7 (19%) patients with high hs-cTnT and 2 (4%) patients with normal hs-cTnT. The rate of cardiac death was higher in patients with high hs-cTnT than in those with normal hs-cTnT (log-rank, P<0.01). Cox proportional hazard analysis showed that hs-cTnT was an independent predictor of cardiac death. The events rate was higher in patients with high hs-cTnT than in those with normal hs-cTnT (log-rank, P<0.01): cardiac death, ventricular tachyarrhythmias or hospitalization for heart failure occurred in 24 (65%) patients with high hs-cTnT and 11 (20%) patients with normal hs-cTnT. CONCLUSIONS: Elevated hs-cTnT was linked with adverse outcomes in CS patients, suggesting it is an effective prognostic biomarker.
No takes yet. Share an insight, caveat, or question.
Takaya et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: